BioTech
-
Early data released on Moderna’s efforts to turn mRNA into medicine
LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on…
Read More » -
GLP-1 drug may help with Parkinson’s disease, study reports
The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but…
Read More » -
STAT+: Roivant CEO: New deals could ‘materialize later this year’
Can Roivant’s business model survive its success? Roivant Sciences announced two pieces of news Tuesday: that its drug brepocitinib hit…
Read More » -
Biogen, Eisai, Aardvark Therapeutics, etc.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
WuXi and Congress, Boundless Bio, etc.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Why the world’s most expensive drug might be worth the price
The staff of the Institute for Clinical and Economic Review, or ICER, are known as the nerds of the drug…
Read More » -
Lenmeldy, GLP-1s and Oprah, autoimmune disease
Today is the inaugural publishing day for Adam’s Biotech Scorecard — a subscriber-only newsletter offering senior reporter Adam Feuerstein’s no-holds-barred…
Read More » -
Intra-Cellular’s depression drug, the MASH market
I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s…
Read More » -
Mirador, a new biotech startup, launches with $400 million
What happens after you close a nearly $11 billion acquisition? Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was…
Read More » -
Blackstone Life Sciences, Merck, Bluebird Bio
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the details on a potentially major…
Read More »